杏林製薬の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2023/09/25 | 1,800 | 1,830 | 1,791 | 1,824 | +42 | +2.4% | 133,800 |
2023/09/22 | 1,796 | 1,803 | 1,780 | 1,782 | -26 | -1.4% | 78,500 |
2023/09/21 | 1,806 | 1,824 | 1,803 | 1,808 | +1 | +0.1% | 67,300 |
2023/09/20 | 1,834 | 1,834 | 1,805 | 1,807 | -27 | -1.5% | 102,400 |
2023/09/19 | 1,815 | 1,834 | 1,815 | 1,834 | +3 | +0.2% | 58,500 |
2023/09/15 | 1,812 | 1,842 | 1,801 | 1,831 | +24 | +1.3% | 217,700 |
2023/09/14 | 1,800 | 1,810 | 1,790 | 1,807 | +8 | +0.4% | 110,800 |
2023/09/13 | 1,800 | 1,801 | 1,789 | 1,799 | -1 | -0.1% | 68,500 |
2023/09/12 | 1,779 | 1,802 | 1,778 | 1,800 | +22 | +1.2% | 55,200 |
2023/09/11 | 1,773 | 1,780 | 1,764 | 1,778 | +4 | +0.2% | 41,400 |
2023/09/08 | 1,783 | 1,795 | 1,771 | 1,774 | -7 | -0.4% | 102,700 |
2023/09/07 | 1,775 | 1,785 | 1,770 | 1,781 | -1 | -0.1% | 83,600 |
2023/09/06 | 1,798 | 1,798 | 1,776 | 1,782 | -9 | -0.5% | 42,600 |
2023/09/05 | 1,787 | 1,800 | 1,779 | 1,791 | +2 | +0.1% | 84,200 |
2023/09/04 | 1,788 | 1,792 | 1,775 | 1,789 | -5 | -0.3% | 60,600 |
2023/09/01 | 1,773 | 1,797 | 1,766 | 1,794 | +20 | +1.1% | 130,700 |
2023/08/31 | 1,766 | 1,776 | 1,765 | 1,774 | +5 | +0.3% | 159,500 |
2023/08/30 | 1,769 | 1,778 | 1,763 | 1,769 | -1 | -0.1% | 74,900 |
2023/08/29 | 1,749 | 1,770 | 1,748 | 1,770 | +21 | +1.2% | 75,500 |
2023/08/28 | 1,755 | 1,758 | 1,745 | 1,749 | +4 | +0.2% | 32,400 |
2023/08/25 | 1,736 | 1,753 | 1,732 | 1,745 | +6 | +0.3% | 92,000 |
2023/08/24 | 1,731 | 1,745 | 1,727 | 1,739 | -1 | -0.1% | 42,500 |
2023/08/23 | 1,724 | 1,743 | 1,724 | 1,740 | +4 | +0.2% | 45,300 |
2023/08/22 | 1,735 | 1,741 | 1,725 | 1,736 | +2 | +0.1% | 52,100 |
2023/08/21 | 1,734 | 1,741 | 1,728 | 1,734 | +6 | +0.3% | 50,500 |
2023/08/18 | 1,711 | 1,729 | 1,710 | 1,728 | +15 | +0.9% | 62,300 |
2023/08/17 | 1,728 | 1,731 | 1,712 | 1,713 | -15 | -0.9% | 103,900 |
2023/08/16 | 1,732 | 1,735 | 1,718 | 1,728 | -16 | -0.9% | 114,100 |
2023/08/15 | 1,746 | 1,750 | 1,733 | 1,744 | -13 | -0.7% | 113,400 |
2023/08/14 | 1,783 | 1,790 | 1,756 | 1,757 | -24 | -1.3% | 69,500 |
2023/08/10 | 1,761 | 1,781 | 1,756 | 1,781 | +20 | +1.1% | 54,700 |
2023/08/09 | 1,750 | 1,764 | 1,737 | 1,761 | +11 | +0.6% | 49,900 |
2023/08/08 | 1,730 | 1,755 | 1,730 | 1,750 | +21 | +1.2% | 63,400 |
2023/08/07 | 1,707 | 1,738 | 1,707 | 1,729 | +19 | +1.1% | 57,800 |
2023/08/04 | 1,730 | 1,730 | 1,705 | 1,710 | -25 | -1.4% | 112,700 |
2023/08/03 | 1,775 | 1,775 | 1,721 | 1,735 | -73 | -4% | 193,600 |
2023/08/02 | 1,800 | 1,813 | 1,795 | 1,808 | +6 | +0.3% | 142,700 |
2023/08/01 | 1,784 | 1,802 | 1,782 | 1,802 | +29 | +1.6% | 150,000 |
2023/07/31 | 1,795 | 1,803 | 1,767 | 1,773 | -7 | -0.4% | 101,100 |
2023/07/28 | 1,761 | 1,785 | 1,760 | 1,780 | +3 | +0.2% | 104,000 |
2023/07/27 | 1,767 | 1,777 | 1,759 | 1,777 | +1 | +0.1% | 46,900 |
2023/07/26 | 1,760 | 1,778 | 1,758 | 1,776 | +12 | +0.7% | 59,200 |
2023/07/25 | 1,770 | 1,774 | 1,759 | 1,764 | -6 | -0.3% | 62,700 |
2023/07/24 | 1,755 | 1,770 | 1,749 | 1,770 | +19 | +1.1% | 67,000 |
2023/07/21 | 1,747 | 1,751 | 1,738 | 1,751 | +16 | +0.9% | 63,700 |
2023/07/20 | 1,747 | 1,751 | 1,732 | 1,735 | -14 | -0.8% | 40,400 |
2023/07/19 | 1,746 | 1,749 | 1,735 | 1,749 | +16 | +0.9% | 60,800 |
2023/07/18 | 1,713 | 1,734 | 1,713 | 1,733 | +16 | +0.9% | 42,400 |
2023/07/14 | 1,718 | 1,724 | 1,706 | 1,717 | +3 | +0.2% | 62,900 |
2023/07/13 | 1,719 | 1,722 | 1,704 | 1,714 | +1 | +0.1% | 73,900 |
151~
200
件表示中 / 3451件
類似銘柄と比較する
現在ご覧いただいている「杏林製薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
杏林製薬 | 182,200円 | +2.6% | +11.5% | 2.85% | 21.36倍 | 0.83倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
持田薬 | 321,500円 | -1.2% | -37.3% | 2.49% | 25.90倍 | 0.90倍 |
|
医薬中堅。高脂血症薬、降圧薬など循環器系得意。婦人科系にも強み。消化器系育成。化粧品も |
ジーエヌアイ | 239,400円 | +52.1% | +23.3% | 0.00% | 16.92倍 | 3.53倍 |
|
創薬ベンチャー。米国で人工骨も。中国の特発性肺線維症薬で高シェア、米中に研究開発機能 |
鳥居薬 | 403,500円 | +7.3% | +16.8% | 2.97% | 24.13倍 | 0.94倍 |
|
JT傘下。自社製品の腎・透析、アレルゲン等の開発強化。柱の抗HIV薬の販売権喪失が直撃 |
ゼリア新薬 | 210,900円 | +6.8% | +18.7% | 2.09% | 13.28倍 | 1.23倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
市場注目の銘柄
チャート関連のコラム